June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Contrast Sensitivity- A meaningful way to assess health-related quality of life and ability to perform activities of daily living in patients with glaucoma.
Author Affiliations & Notes
  • priyanka gogte
    Glaucoma Research, Wills Eye Hospital, Philadelphia, PA
  • Lisa A Hark
    Glaucoma Research, Wills Eye Hospital, Philadelphia, PA
  • Eric Spaeth
    Glaucoma Research, Wills Eye Hospital, Philadelphia, PA
  • Jesse Richman
    Glaucoma Research, Wills Eye Hospital, Philadelphia, PA
  • Sheryl Wizov
    Glaucoma Research, Wills Eye Hospital, Philadelphia, PA
  • Michael Waisbourd
    Glaucoma Research, Wills Eye Hospital, Philadelphia, PA
  • George L Spaeth
    Glaucoma Research, Wills Eye Hospital, Philadelphia, PA
  • Footnotes
    Commercial Relationships priyanka gogte, None; Lisa Hark, None; Eric Spaeth, U.S Patent No.8,042,946 (P); Jesse Richman, U.S Patent No.8,042,946 (P); Sheryl Wizov, None; Michael Waisbourd, None; George Spaeth, U.S Patent No.8,042,946 (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2097. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      priyanka gogte, Lisa A Hark, Eric Spaeth, Jesse Richman, Sheryl Wizov, Michael Waisbourd, George L Spaeth; Contrast Sensitivity- A meaningful way to assess health-related quality of life and ability to perform activities of daily living in patients with glaucoma.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2097.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Currently there is no single test that correlates psychophysical testing, Quality of Life (QoL) and the ability to perform activities of daily living (ADL) in patients with glaucoma. The purpose of this study was to assess if contrast sensitivity (CS) can be used as this tool. CS was measured using a novel method, the Spaeth/Richman contrast sensitivity (SPARCS) test. The relationship between CS by SPARCS with QoL, ability to perform ADL, CS by Pelli-Robson (PR) and visual field (VF) defects was investigated.

Methods: Patients with moderate stage glaucoma were recruited from the Wills Eye Hospital Glaucoma Service. The CS was measured using SPARCS and PR tests. Additional clinical parameters were also measured and reported separately. Humphrey visual field (VF) testing was conducted. The QoL was assessed using the National Eye Institute’s Visual Functioning Questionnaire (NEI-VFQ 25) and the Glaucoma Symptom Scale (GSS). The ability to function was also measured objectively using the Compressed Assessment of Ability Related to Vision (CAARV). Main outcomes included correlation between CS with measures of QoL, ADL, and VF defects. Spearman correlation coefficients were used and P value < 0.05 was considered significant.

Results: One hundred and sixty-one subjects (females: n = 86, 53.4%) were included in the final analysis. The mean age (range) was 64.6 (30-83) years. SPARCS total score significantly correlated with the CAARV total score in both the better (r= 0.398, P <.001) and worse (r=0.326, P =0.001) eye. The correlation between the total NEI-VFQ-25 and SPARCS scores were significant only in the worse (r=0.353, P <.001) eye. SPARCS and PR showed a significant correlation in both the better (r=0.564, P<.001) and worse (r=0.654, P<.001) eye. SPARCS score correlated well with the VF defect in both the better (r=0.589, P<.001) and worse (r=0.792 P<.001) eye. A parallel relationship was also detected between worsening visual fields and CS as measured by SPARCS.

Conclusions: There was a significant correlation between a patient’s ability to perform ADLs, their reported QoL, and the results of their CS test using the SPARCS. The decrease in CS in these patients also paralleled the worsening of their VF tests. CS measured by SPARCS is a potentially useful tool in the overall assessment of patients with glaucoma.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×